Biphasic effects of atorvastatin on inflammation

Pakistan Journal of Pharmaceutical Sciences

Volumn 21, Issue 2, 2008, Pages 125-130

  Garjani, Alireza ^a   Andalib, Sina ^a   Ziaee, Mojtaba ^a   Maleki Dizaji, Nasrin ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory; Atorvastatin; Pro inflammatory; Statins

Indexed keywords

ATORVASTATIN; CARBOXYMETHYLCELLULOSE; CARRAGEENAN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; MEVALONIC ACID; MEVINOLIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTIINFLAMMATORY AGENT; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HYPERLIPIDEMIA; INFLAMMATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PAW EDEMA; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; EDEMA; HINDLIMB; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; CARRAGEENAN; EDEMA; HEPTANOIC ACIDS; HINDLIMB; INFLAMMATION; MALE; MEVALONIC ACID; MICE; PYRROLES; RATS; RATS, WISTAR;

EID: 44449141539     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Arnaud C, Braunersreuther V and Mach F (2005). Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc. Med., 15(6): 202-206. (Pubitemid 41338006)
2. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ and Posvar EL (1996). Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther., 60: 687-695. (Pubitemid 27025917)
3. Coward Wr, Marei A, Yang A, Vasa-Nicotera MM and Chow Sc (2006). Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J. Immunol., 1; 176(9):5284-5292.
4. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P and Salmona M (2001). In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 21: 1327-1332. (Pubitemid 34219840)
5. Downs JR, Clarfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W and Gotto AM (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA, 279: 1615-1622. (Pubitemid 28248586)
6. Fessler MB, Young SK, Jeyaseelan S, Lieber JG, Arndt PG, Nick JA and Worthen GS (2005). A role for Hydroxy-Methylglutaryl Coenzyme A Reductase in pulmonary inflammation and host defense. Am. J. Respiratory and Critical Care Medicine, 171: 606-615. (Pubitemid 40365416)
7. Fossati P and Principe L (1982). Serum triglycerides determined colorimetrically with an enzyme that produce hydrogen peroxide. Clinical Chemistry, 28: 2077-2080. (Pubitemid 12034053)
8. Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360: 7-22.
9. Heart Protection Study Collaborative Group (2003). MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet, 361: 2005-2016.
10. Maleki N, Garjani A, Nazemiyeh H, Nilfouroushan N, Eftekhar Sadat and Allameh Z (2001). Potent antiinflammatory activities of hydroalcoholic extract from aerial parts of Stachys Inflata on rats. J. Ethnopharmacology, 75: 213-218. (Pubitemid 32297736)
11. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC and Braunwald E (1998). Inflammation, pravastatin and risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation, 98: 839-844. (Pubitemid 28397432)
12. Scandinavian Simvastatin Survival Study (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344: 1383-1389.
13. Schonbeck U and Libby P (2004). Inflammation, Immunity, and HMG-CoA Reductase Inhibitors Statins as Antiinflammatory Agents. Circulation, 109(Suppl II): II-18 -II-26. (Pubitemid 38724152)
14. Shepherd J, Cobbe SM and Ford I (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 333: 1301-1307.
15. Steinberg D (2005). Hypercholestrolemia and inflammation in atherogenesis: two sides of the same coin. Mol. Nutr. Food Res., 49(11): 995-998. (Pubitemid 41735560)
16. Stoll G and Bendszus M (2006). Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke, 37(7): 1923-1932 (Pubitemid 44297753)
17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339: 1349-1357.
18. Watson DA (1960). Simple method for the determination of serum cholesterol. Clinical Chemistry Acta, 5: 589.